Specifically, future studies could investigate the direct inhibition of XOD activity by HD and explore the effects of specific mutations in the binding sites of URAT1, GLUT9, and ABCG2 on HD’s binding affinity. This evidence concerns the gene SLC2A9 and Huntington disease.